Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures can feel like a maze. Enliven Therapeutics’ pipeline updates, cash-runway tables, and trial safety data sprawl across hundreds of pages. If you have searched for “understanding Enliven Therapeutics SEC documents with AI” or “Enliven Therapeutics SEC filings explained simply,” you are not alone—investors regularly struggle to locate the data that drives this precision-oncology stock.
Stock Titan solves that problem. Our AI-powered summaries dissect every Enliven Therapeutics quarterly earnings report 10-Q filing, annual report, and 8-K the moment they appear on EDGAR. Need alerts on Enliven Therapeutics Form 4 insider transactions real-time? We flag each entry, spotlighting notable Enliven Therapeutics insider trading Form 4 transactions alongside context such as share price, option exercise, and historical patterns. Side-by-side comparisons, cash-burn ratios, and dilution math are pulled automatically, turning an Enliven Therapeutics earnings report filing analysis into a five-minute read.
The details that matter most in early-stage biotech rarely sit on page one. Our platform highlights milestone payment clauses, going-concern language, and patent timelines inside an Enliven Therapeutics annual report 10-K simplified synopsis. You can drill into option grants through every Enliven Therapeutics executive stock transactions Form 4, review board pay with the Enliven Therapeutics proxy statement executive compensation section, and receive push notifications when an Enliven Therapeutics 8-K material events explained alert covers trial data or FDA designations. All filings update in real time, backed by clean, plain-English AI commentary that lets you focus on decisions, not document hunting.
Samuel Kintz, President & CEO and director of Enliven Therapeutics (ELVN), reported two open-market sales under a Rule 10b5-1 plan adopted November 15, 2024. On 09/17/2025 he sold 5,000 shares for a weighted-average price of $19.0946, leaving beneficial ownership of 922,892 shares of record held by The Kintz & Egan Trust Dated March 30, 2019 for which he is trustee. On 09/19/2025 he sold 1,000 shares for a weighted-average price of $20.25, reducing beneficial ownership to 921,892 shares. The Form 4 was executed by power of attorney on 09/19/2025 and discloses the plan-based nature of the trades and willingness to provide per-trade price details upon request.
Enliven Therapeutics (ELVN) Form 144 notice shows a proposed sale of 12,500 common shares through Jefferies with an aggregate market value of $249,125, with an approximate sale date of 09/19/2025. The filer states these shares were acquired as founder shares on 09/01/2019 from Enliven Therapeutics. The filing reports 59,000,000 shares outstanding for the issuer.
The filing also discloses recent insider transactions: 24,500 shares sold by Joseph Lyssikatos during July–August 2025 for total gross proceeds of $526,862.01 across three transactions. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
FAQ
What is the current stock price of Enliven Therapeutics (ELVN)?
What is the market cap of Enliven Therapeutics (ELVN)?
